【摘要】 [目的] 研究归芪方对糖尿病(DM)大鼠早期肾脏病变的保护作用及其机制。[方法] Wistar大鼠腹腔注射链脲佐菌素建立DM模型,随机分为DM模型组(B组)、苯那普利治疗组(C组)、归芪方治疗组(D组),另设正常对照组(A组)。实验第8周时,观察各组血糖、血脂、肾重/体重及蛋白尿的改变,放射免疫法测定血浆及肾组织血管紧张素Ⅱ(AngⅡ),半定量RT PCR法检测肾脏转化生长因子 β1(TGF β1)mRNA的表达。[结果] 归芪方可以降低高血糖、高血脂,并且在改善肾脏肥大及抑制肾脏 TGF β1 mRNA 表达方面优于苯那普利(P < 0.01, <0.05),归芪方还能降低肾内和血浆AngⅡ水平(P<0.01)。[结论] 归芪方可调节糖、脂代谢紊乱,降低 AngⅡ水平,抑制肾脏TGF β1 mRNA的表达,改善肾功能,延缓DM的进展。更多还原

【Abstract】 Objective] To investigate the protective mechanism of Guiqi mixture(GM) on renal diseases of early stage in diabetic rats. [Methods] The diabetic animal model was made by single intraperitoneal injection of 60 mg/kg streptozotocin(STZ) and treated with GM or enala pril. After 8 weeks of treatment, blood glucose, lipid, ratio of renal weight and body weight, urine β 2 microglobin were measured. The expression of renal transforming growth factor β 1 (TGF β 1) mRNA in kidney was determined by RT PCR and angiotensinⅡ(AngⅡ) concentration in plasma and kidney was investigated by radioimmunoassay. [Results] GM lowered the blood glucose and lipid, and it was superior to enalapril in reducing the expression of TGF β 1 mRNA and hypertrophic index (P< 0.01 , < 0.05 ). GM modulated intrarenal and plasma AngⅡ levels (P< 0.01 ). [Conclusion] GM may alleviate the disorder of blood glucose and lipid, slow down the progress of renal diseases in diabetic rats by inhibiting the expression of TGF β 1 mRNA and lowering the level of AngⅡ.更多还原